Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effisayil® REP
NCT06013969Phase 4Completed
- Sponsor
- LEO Pharma
- Start
- Oct 2023
- Primary completion
- May 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 4 trial of spesolimab in generalized pustular psoriasis (GPP), sponsored by LEO Pharma. Started Oct 2023; status: completed.
02
Drugs
spesolimab
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on NCT06013969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06013969.